menu
    • menu
    [{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Afaxys Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Agile Therapeutics \/ Agile Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Agile Therapeutics"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Patch","sponsorNew":"Agile Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"vitaCare Prescription Services","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Agile Therapeutics \/ vitaCare Prescription Services","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ vitaCare Prescription Services"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Patch","sponsorNew":"Agile Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Insud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Agile Therapeutics \/ Insud Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Insud Pharma"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Insud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Agile Therapeutics \/ Insud Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Insud Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Agile Therapeutics

    Menu

    Agile Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Insud Pharma

                            Deal Size : $45.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.

                            Details : Through the aquisition, Agile Therapeutics will combine with Insud Pharma and focus on the commercialization of Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system contraceptive.

                            Product Name : Twirla

                            Product Type : Small molecule

                            Upfront Cash : $45.0 million

                            August 26, 2024

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Insud Pharma

                            Deal Size : $45.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Insud Pharma

                            Deal Size : $45.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.

                            Details : Through the merger, Agile Therapeutics will combine with Insud Pharma and focus on the commercialization of Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system contraceptive.

                            Product Name : Twirla

                            Product Type : Small molecule

                            Upfront Cash : $45.0 million

                            June 26, 2024

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Insud Pharma

                            Deal Size : $45.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Undisclosed

                            Deal Size : $7.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            This Women's Healthcare Company Raised $7.5 Million in a Public Offering and Says it's Targeting $25 to $30 Mi...

                            Details : The net proceeds will be used for the Twirla (levonorgestrel and ethinyl estradiol), the first and only combined hormonal once-weekly birth control patch delivering a low dose of estrogen.

                            Product Name : Twirla

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 03, 2023

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Undisclosed

                            Deal Size : $7.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : vitaCare Prescription Services

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®

                            Details : The agreement aims to expand patient access and streamline fulfillment for Twirla (levonorgestrel ethinyl estradiol) transdermal system, a once-weekly combined hormonal contraceptive (CHC) patch, indicated for use as a method of contraception by women.

                            Product Name : Twirla

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 13, 2023

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : vitaCare Prescription Services

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation

                            Details : TWIRLA is a combination of levonorgestrel, a progestin, ethinyl estradiol and estrogen. It is a hormonal contraceptives lower the risk of becoming pregnant primarily by suppressing ovulation.

                            Product Name : Twirla

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 01, 2023

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentati...

                            Details : Approval of Twirla (levonorgestrel) was based on SECURE study, which demonstrated safety in a large diverse group of women in a clinical trial setting.

                            Product Name : Twirla

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 05, 2022

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the A...

                            Details : Twirla (levonorgestrel and ethinyl estradiol) transdermal system is combined hormonal contraceptive patch, indicated for use as a method of contraception by women of reproductive potential with a body mass index < 30 kg/m2.

                            Product Name : Twirla

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 07, 2022

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Agile Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Recipient : Afaxys Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Agile Therapeutics and Afaxys Partner to Expand Access to Twirla® (Levonorgestrel and Ethinyl Estradiol) Tran...

                            Details : This strategic agreement with Afaxys, a recognized leader in the public health system, will help ensure that Twirla is available, accessible and affordable to a much broader group of patients who can benefit from it.

                            Product Name : Twirla

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 10, 2022

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Recipient : Afaxys Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth